logo
The Baseline
23 Sep 2025
Five stocks to buy from analysts this week - September 23, 2025
By Abdullah Shah

1. Bharti Airtel

Geojit BNP Paribas maintains its ‘Buy’ rating on this telecom provider, with a target price of Rs 2,123, an upside of 9.5%. Analyst Gopika Gopan attributes the positive outlook to the company's significant expansion in its fixed wireless access (FWA) and home-pass networks. 

In Q1FY26, Bharti Airtel's revenue grew 28.6% YoY to Rs 49,971.4 crore, fueled by strong performance in the Indian market and a recovery in Africa. Growth in India was driven by steady performance in mobile and home services, with an average revenue per user (ARPU) of Rs 250. Net profit surged 43% YoY to Rs 5,947.9 crore due to lower access charges. The company also added 7 lakh postpaid customers during the quarter, bringing its total base to 2.7 crore.

Gopan highlights that the company's portfolio premiumisation and continued growth in 5G shipments will drive performance across all segments. She adds that its focus on acquiring high-quality customers and expanding its fibre and FWA networks will be catalysts for margin growth. She expects revenue and net profit to grow at a CAGR of 16.7% and 25.2%, respectively, over FY26-27.

2. Jindal Stainless:

ICICI Direct reiterates its ‘Buy’ rating on this iron/steel products manufacturer with a target price of Rs 940, indicating an upside of 17.4%. Analysts Shashank Kanodia and Manisha Kesari cite industry tailwinds and capacity expansion as key drivers for long-term growth. They also expect margin expansion from a richer product mix, and increased backward integration.

Analysts note that India's stainless steel demand is projected to grow at a 7% CAGR to 6.5 MTPA by FY30, driven by applications in the automotive and process industries. Additionally, emerging sectors like green hydrogen, nuclear energy, and defence offer demand visibility. The company is well-positioned to capitalise on this growth, with plans to establish a 1.2 MTPA melting shop in Indonesia by FY27, lifting total capacity to 4.2 MTPA.

Kanodia and Kesari highlight the management's focus on expanding its downstream capacity with new hot-rolled and cold-rolled processing lines in Odisha. The acquisition of a 0.6 MTPA cold rolling mill in Gujarat and a joint venture for a 2 lakh MTPA nickel pig iron plant are also expected to improve margins. Analysts expect the company to deliver revenue, EBITDA, and net profit CAGRs of 9.2%, 12.2%, and 16.3% respectively, over FY26-28.

3. Prince Pipes & Fittings:

Motilal Oswal retains a ‘Buy’ rating on this smallcap plastic pipes & fittings manufacturer with a target price of Rs 440, an upside of 27.6%. Analysts Meet Jain and Sumant Kumar expect medium-term growth to be driven by new capacity in Bihar, expansion of the chlorinated polyvinyl chloride (CPVC) business, and rising demand in tier-2/3 markets. They also forecast margin expansion from higher utilisation and a richer product mix.

While management acknowledges Q2 is a seasonally weak quarter, it anticipates a recovery in H2FY26. This rebound is expected to be driven by inventory restocking, GST-related demand for building materials, and increased consumption. The company plans to commission a new facility in Bihar by the end of H1FY26, adding 45-50 kilotonnes per annum of capacity and strengthening its foothold in the high-potential East India market.

Analysts believe the company is well-positioned to increase its market share in the CPVC business, supported by its partnership with Lubrizol for CPVC compounds. Additionally, government schemes like PMAY (Housing for All) are expected to drive demand over the medium term. Jain and Kumar forecast the company to deliver revenue, EBITDA, and net profit CAGRs of 14.4%, 45.8%, and 100% respectively, over FY26-27.

4. GR Infraprojects:

Axis Securities maintains its ‘Buy’ call on this infrastructure company with a target price of Rs 1,540, an upside of 19.7%. Analysts Uttam Kumar Srimal and Shikha Doshi believe the company is poised for growth, citing the government's strong push for infrastructure as a key driver for FY26. They expect this national focus on capital expenditure and public-private partnerships to enhance connectivity and drive economic growth.

The company's order book of Rs 19,179 crore in FY25, supplemented by Rs 5,166 crore in lowest-bidder projects, provides strong revenue visibility. With 30 active projects nationwide, analysts highlight the company's proven execution capabilities and effective project management.

GR Infraprojects is actively diversifying beyond its core roads and highways portfolio into sectors like railways, tunnels, ropeways, and power transmission. It is also exploring new opportunities in multi-modal logistic parks, airport runways, and renewable energy projects.

Srimal and Doshi anticipate a robust bidding pipeline in engineering, procurement, and construction (EPC) and hybrid annuity model (HAM) projects to drive strong order intake. Consequently, they forecast the company will deliver a revenue and net profit CAGR of 12.5% and 8.4% over FY26-27.

5. Abbott India:

Sharekhan retains its ‘Buy’ rating on this pharmaceutical company, with a target price of Rs 34,470, an upside of 14%. Analysts believe a strong distribution network, continued expansion into tier-II & III cities, and a healthy product pipeline will fuel topline growth.

In Q1FY26, Abbott India's revenue and net profit both grew 11.5% YoY. Strong brand performance and marketing initiatives drove revenue growth, while lower raw material costs bolstered profitability. Underscoring its innovation, the company has launched over 100 products in the last 12 years, positioning it for sustained performance through a mix of legacy brands and new offerings.

Analysts identify the company's strong brand recall as a key growth driver, supported by the upcoming marketing and distribution of Novo Nordisk's GLP-1 in India, which should provide a near-term catalyst. Sharekhan forecasts the firm’s revenue and net profit to deliver a CAGR of 9.4% and 12.6% over FY26-27E, respectively.

 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)

More from The Baseline
More from Trendlyne Analysis
Recommended